Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pimonidazole is a small molecule belonging to the nitroimidazole class, primarily used as a hypoxia marker in research and clinical diagnostics. It is selectively reduced in hypoxic environments—such as those found within solid tumors—where it forms stable adducts with thiol groups in proteins, peptides, and amino acids. This property allows for the identification and quantification of hypoxic cells using immunohistochemical techniques. Pimonidazole has also been investigated for its radiosensitizing properties due to its ability to deplete radioprotective thiol compounds in tumor cells, potentially making them more susceptible to radiation therapy. Its main applications are as a diagnostic tool for assessing tumor hypoxia in cancers such as prostate cancer and head and neck cancer[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pimonidazole.